The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with dostarlimab plus chemotherapy in the RUBY trial.
 
Mansoor Raza Mirza
Leadership - Karyopharm Therapeutics; Sera Prognostics
Stock and Other Ownership Interests - Karyopharm Therapeutics; Sera Prognostics
Honoraria - Allarity Therapeutics; AstraZeneca; Geneos; Genmab/Seattle Genetics; GlaxoSmithKline; Merck; Mersana; Roche; Takeda; Zai Lab
Consulting or Advisory Role - AstraZeneca; Genmab; GlaxoSmithKline; Karyopharm Therapeutics; Pfizer
Research Funding - Apexigen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Tesaro (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro
Other Relationship - European Network of Gynaecological Oncologic Trials; European Society for Gynaecological Oncology; Gynecological Cancer InterGroup
 
Sudarshan Sharma
No Relationships to Disclose
 
Henrik Roed
No Relationships to Disclose
 
Lisa M. Landrum
No Relationships to Disclose
 
Lucy Gilbert
Honoraria - GlaxoSmithKline; Merck; Peervoice
Consulting or Advisory Role - CanariaBio; Eisai; GlaxoSmithKline; GOG Foundation; Immunogen; Kora Healthcare; Merck; Merck/Eisai
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Corcept Therapeutics (Inst); Esperas Pharma (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Immunogen (Inst); IMV (Inst); IMV (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Roche (Inst); Shattuck Labs (Inst); Sutro BioPharma Inc (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Corcept Therapeutics; EndomEra; GlaxoSmithKline; GOG Foundation; Merck; Zentalis
 
Michael A. Gold
Travel, Accommodations, Expenses - ASCCP
 
Zoltán Novák
Honoraria - AstraZeneca; Richter Gedeon; Sofmedica
Speakers' Bureau - MSD Oncology; Richter Gedeon
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Mitchell Edelson
Employment - Merck (I); Pfizer (I)
Stock and Other Ownership Interests - Merck (I)
Honoraria - GlaxoSmithKline
Travel, Accommodations, Expenses - Intuitive Surgical
 
Mihai Meirovitz
No Relationships to Disclose
 
John Paul Diaz
Speakers' Bureau - AstraZeneca
Research Funding - Merck (Inst)
 
Greet Huygh
No Relationships to Disclose
 
Joseph Buscema
Employment - Arizona Oncology
Leadership - Arizona Oncology
Stock and Other Ownership Interests - McKesson
Honoraria - Caris Life Sciences
Consulting or Advisory Role - Caris Life Sciences; GlaxoSmithKline
 
Bhavana Pothuri
Honoraria - Bio Ascend; OncLive; PER; Projects in Knowledge; YALE UNIVERSITY
Consulting or Advisory Role - AstraZeneca; Celsion; Curio Science; Eisai; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; Incyte; Incyte; InxMed; Lilly; Merck; Mersana; Onconova Therapeutics; Peerview; R-Pharm; Regeneron; Seagen; Signatera; Sutro Biopharma; WebMD
Research Funding - Acrivon Therapeutics (Inst); Agenus (Inst); AstraZeneca (Inst); Celgene (Inst); Celsion (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); InxMed (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mersana (Inst); Novocure (Inst); NRG Oncology (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Sutro Biopharma (Inst); Takeda (Inst); Tesaro (Inst); Toray Industries (Inst); VBL Therapeutics (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - GOG Foundation; Merck; Seagen
Other Relationship - Society of Gynecologic Oncology
 
Helen Dinkelspiel Eshed
Honoraria - honorarium for participation in a speaker’s bureau for Immunogen
 
Robert L. Coleman
Employment - US Oncology; Vaniam Group
Leadership - Onxeo
Stock and Other Ownership Interests - McKesson/US Oncology Network
Consulting or Advisory Role - Abbvie; Agenus; Alkermes; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; GOG Foundation; Gradalis; Immunogen; Karyopharm Therapeutics; Merck; Merck; Novocure; OncoMed; OncXerna Therapeutics
Research Funding - Alkermes; Amgen (Inst); AstraZeneca/MedImmune; Clovis Oncology (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck; Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (I)
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Brian M. Slomovitz
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Eisai; EQRx; Genentech; Genmab; Gilead Sciences; GlaxoSmithKline; GOG Foundation; Lilly; Merck; Nuvation Bio; Onconova Therapeutics; Onconova Therapeutics; Regeneron; Seagen
 
Rumen Kostadinov
Employment - GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline
 
Shadi Stevens
Employment - GlaxoSmithKline; GlaxoSmithKline
 
Graziana Ronzino
No Relationships to Disclose
 
Matthew A. Powell
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline/Tesaro; GOG partners; Immunogen; Merck; Seagen; Tesaro
Research Funding - GlaxoSmithKline/Tesaro (Inst)